Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab
Crossref DOI link: https://doi.org/10.1007/s11060-015-2031-7
Published Online: 2015-12-31
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bumes, Elisabeth
Rzonsa, Sarah
Hutterer, Markus
Proescholdt, Martin
Bogdahn, Ulrich
Riemenschneider, Markus J.
Uhl, Martin
Wendl, Christina
Hau, Peter
Text and Data Mining valid from 2015-12-31